- Home
- ERJ vs JAZZ Comparison
ERJ vs JAZZ Comparison
Compare ERJ & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERJ
- JAZZ
- Stock Information
- Founded
- ERJ 1969
- JAZZ 2003
- Country
- ERJ Brazil
- JAZZ Ireland
- Employees
- ERJ N/A
- JAZZ N/A
- Industry
- ERJ Aerospace
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ERJ Industrials
- JAZZ Health Care
- Exchange
- ERJ Nasdaq
- JAZZ Nasdaq
- Market Cap
- ERJ 7.7B
- JAZZ 6.1B
- IPO Year
- ERJ 2000
- JAZZ 2007
- Fundamental
- Price
- ERJ $45.66
- JAZZ $115.90
- Analyst Decision
- ERJ Buy
- JAZZ Strong Buy
- Analyst Count
- ERJ 5
- JAZZ 13
- Target Price
- ERJ $46.25
- JAZZ $187.15
- AVG Volume (30 Days)
- ERJ 1.8M
- JAZZ 1.3M
- Earning Date
- ERJ 05-06-2025
- JAZZ 05-06-2025
- Dividend Yield
- ERJ N/A
- JAZZ N/A
- EPS Growth
- ERJ 144.89
- JAZZ 41.75
- EPS
- ERJ 0.42
- JAZZ 8.65
- Revenue
- ERJ $5,727,525,762.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- ERJ N/A
- JAZZ $7.60
- Revenue Next Year
- ERJ $13.04
- JAZZ $3.47
- P/E Ratio
- ERJ $107.86
- JAZZ $13.41
- Revenue Growth
- ERJ 35.67
- JAZZ 6.12
- 52 Week Low
- ERJ $25.05
- JAZZ $95.49
- 52 Week High
- ERJ $56.61
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- ERJ 50.30
- JAZZ 50.76
- Support Level
- ERJ $43.94
- JAZZ $111.20
- Resistance Level
- ERJ $45.92
- JAZZ $117.09
- Average True Range (ATR)
- ERJ 1.11
- JAZZ 4.20
- MACD
- ERJ 0.45
- JAZZ 2.33
- Stochastic Oscillator
- ERJ 80.15
- JAZZ 87.31
About ERJ Embraer S.A.
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the various segments namely Commercial Aviation, Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.